NCT02017860View on ClinicalTrials.gov

Study to Collect and Assess Long-term Safety of Everolimus in Patients Who Are on Everolimus Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator.

PHASE2CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

January 16, 2014

Primary Completion Date

April 25, 2019

Study Completion Date

April 25, 2019

Conditions
Neoplasms
Interventions
DRUG

Everolimus

Everolimus was provided by the investigator in 2.5 mg or 5 mg tablets for daily oral administration.

Trial Locations (4)

791-0280

Novartis Investigative Site, Matsuyama

060 8648

Novartis Investigative Site, Sapporo

540-0006

Novartis Investigative Site, Osaka

362-0806

Novartis Investigative Site, Kitaadachi-gun

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY